IL45620A - Contraceptive composition containing pregnancy-specific beta1-glycoprotein or its antibody - Google Patents
Contraceptive composition containing pregnancy-specific beta1-glycoprotein or its antibodyInfo
- Publication number
- IL45620A IL45620A IL45620A IL4562074A IL45620A IL 45620 A IL45620 A IL 45620A IL 45620 A IL45620 A IL 45620A IL 4562074 A IL4562074 A IL 4562074A IL 45620 A IL45620 A IL 45620A
- Authority
- IL
- Israel
- Prior art keywords
- pregnancy
- glycoprotein
- specific
- antibody
- composition containing
- Prior art date
Links
- 239000003433 contraceptive agent Substances 0.000 title claims 3
- 230000002254 contraceptive effect Effects 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title claims 2
- 108010085648 Pregnancy-Specific beta 1-Glycoproteins Proteins 0.000 title 1
- 102100022018 Pregnancy-specific beta-1-glycoprotein 8 Human genes 0.000 title 1
- 230000035935 pregnancy Effects 0.000 claims description 13
- 208000000995 spontaneous abortion Diseases 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 12
- 241000282693 Cercopithecidae Species 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000013011 mating Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000016087 ovulation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19732345953 DE2345953A1 (de) | 1973-09-12 | 1973-09-12 | Mittel zur konzeptionsverhuetung und zur schwangerschaftsunterbrechung bei primaten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL45620A0 IL45620A0 (en) | 1974-11-29 |
| IL45620A true IL45620A (en) | 1977-10-31 |
Family
ID=5892357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL45620A IL45620A (en) | 1973-09-12 | 1974-09-09 | Contraceptive composition containing pregnancy-specific beta1-glycoprotein or its antibody |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US3957975A (xx) |
| JP (1) | JPS5523255B2 (xx) |
| BE (1) | BE819833A (xx) |
| CA (1) | CA1029656A (xx) |
| DE (1) | DE2345953A1 (xx) |
| DK (1) | DK141986C (xx) |
| FI (1) | FI264974A (xx) |
| FR (1) | FR2242993B1 (xx) |
| GB (1) | GB1484491A (xx) |
| IE (1) | IE41284B1 (xx) |
| IL (1) | IL45620A (xx) |
| IT (1) | IT1058293B (xx) |
| LU (1) | LU70877A1 (xx) |
| NL (1) | NL7411870A (xx) |
| NO (1) | NO743213L (xx) |
| NZ (1) | NZ175376A (xx) |
| SE (1) | SE7411401L (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2745680A1 (de) * | 1977-10-11 | 1979-04-12 | Behringwerke Ag | Kontrazeptives mittel |
| EP0214969A4 (en) * | 1984-04-19 | 1987-12-17 | Univ Queensland | CONTRACEPTIVE METHODS AND DISTRIBUTION SYSTEMS THEREFOR. |
| CA1239346A (en) * | 1985-06-04 | 1988-07-19 | Gursaran P. Talwar | Birth control vaccine |
| US5169835A (en) * | 1989-01-18 | 1992-12-08 | Oklahoma Medical Research Foundation | Pregancy specific proteins applications |
-
1973
- 1973-09-12 DE DE19732345953 patent/DE2345953A1/de not_active Withdrawn
-
1974
- 1974-09-06 NL NL7411870A patent/NL7411870A/xx not_active Application Discontinuation
- 1974-09-06 NO NO743213A patent/NO743213L/no unknown
- 1974-09-06 CA CA208,644A patent/CA1029656A/en not_active Expired
- 1974-09-09 IL IL45620A patent/IL45620A/en unknown
- 1974-09-10 IT IT27151/74A patent/IT1058293B/it active
- 1974-09-10 US US05/504,700 patent/US3957975A/en not_active Expired - Lifetime
- 1974-09-10 LU LU70877A patent/LU70877A1/xx unknown
- 1974-09-10 FI FI2649/74A patent/FI264974A/fi unknown
- 1974-09-10 SE SE7411401A patent/SE7411401L/xx unknown
- 1974-09-11 NZ NZ175376A patent/NZ175376A/xx unknown
- 1974-09-11 IE IE1889/74A patent/IE41284B1/xx unknown
- 1974-09-11 DK DK478774A patent/DK141986C/da active
- 1974-09-12 GB GB39879/74A patent/GB1484491A/en not_active Expired
- 1974-09-12 FR FR7430911A patent/FR2242993B1/fr not_active Expired
- 1974-09-12 BE BE148452A patent/BE819833A/xx unknown
- 1974-09-12 JP JP10445074A patent/JPS5523255B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NO743213L (xx) | 1975-04-07 |
| FR2242993B1 (xx) | 1978-07-28 |
| BE819833A (fr) | 1975-03-12 |
| FR2242993A1 (xx) | 1975-04-04 |
| JPS5523255B2 (xx) | 1980-06-21 |
| US3957975A (en) | 1976-05-18 |
| DK478774A (xx) | 1975-07-07 |
| JPS5058222A (xx) | 1975-05-21 |
| DE2345953A1 (de) | 1975-09-25 |
| NL7411870A (nl) | 1975-03-14 |
| DK141986B (da) | 1980-08-04 |
| IE41284L (en) | 1975-03-12 |
| AU7317074A (en) | 1976-03-18 |
| NZ175376A (en) | 1979-03-16 |
| IL45620A0 (en) | 1974-11-29 |
| LU70877A1 (xx) | 1976-11-24 |
| IE41284B1 (en) | 1979-12-05 |
| SE7411401L (xx) | 1975-03-13 |
| FI264974A (xx) | 1975-03-13 |
| DK141986C (da) | 1980-12-22 |
| CA1029656A (en) | 1978-04-18 |
| GB1484491A (en) | 1977-09-01 |
| IT1058293B (it) | 1982-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jones et al. | The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat | |
| Helmer et al. | Identification of bovine trophoblast protein-1, a secretory protein immunologically related to ovine trophoblast protein-1 | |
| Donker et al. | Effects of prolonged administration of d-penicillamine or captopril in various strains of rats: Brown Norway rats treated with d-penicillamine develop autoantibodies, circulating immune complexes, and disseminated intravascular coagulation | |
| DE69014474T2 (de) | Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente. | |
| Dziegielewska et al. | Blood—cerebrospinal fluid transfer of plasma proteins during fetal development in the sheep | |
| Anderson et al. | Effect of antilymphocytic antibody and antibody fragments on skin-homograft survival and the blood-lymphocyte count in rats | |
| Arai et al. | A double-antibody radioimmunoassay procedure for ovine pituitary prolactin | |
| Ratner et al. | Stimulatory effects of prostaglandin E1 on rat anterior pituitary cyclic AMP and luteinizing hormone release | |
| EP1360962A2 (en) | Interferon tau composition and methods of use | |
| Shadduck et al. | Preparation and neutralization characteristics of an anti‐CSF antibody | |
| Taylor | Effects of long-acting thyroid stimulator (LATS) and LATS protector on human thyroid adenyl cyclase activity | |
| US3928580A (en) | Injectable glycoproteins containing terminal {37 C{38 {0 ends of human immunoglobulins | |
| US3957975A (en) | Use of the pregnancy-specific β1 -glyco-protein and its antibody for contraception | |
| Lange et al. | Immunologic mechanism of transmission of experimental glomerulonephritis in parabiotic rats. | |
| Wallgren et al. | Clinical, endocrinological and spermatological studies after endotoxin in the ram | |
| Sinosich et al. | Pregnancy Associated Plasma Protein‐A: Interaction with Heparin in Crossed Affinity lmmunoelectrophoresis | |
| Lerner et al. | Anti-fertility drugs: novel non-hormonal compounds that inhibit prostaglandin metabolism | |
| Quigg et al. | Studies with antibodies to cultured rat glomerular epithelial cells. Subepithelial immune deposit formation after in vivo injection. | |
| DE3722967A1 (de) | Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung | |
| EP0001443B1 (de) | Mittel zur Konzeptionsverhütung und Schwangerschaftsunterbrechung bei Primaten und Verfahren zu ihrer Herstellung | |
| US5378823A (en) | Nucleic acids encoding type I interferon variants | |
| Liu et al. | Cytotoxic effect of nephrotoxic serum on rat tissue culture. | |
| Torisu et al. | Purification of C′ 3 Inactivator from Human Serum | |
| Meyer et al. | The fate of injected Bence Jones protein | |
| Behrman et al. | Rhesus and squirrel monkey placental specific antigen (s) |